Senolytic Therapy via Immune Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to selectively and safely eliminate senescent cells, which accumulate with aging and contribute to aging-related diseases, due to the heterogeneity of senescent cell populations and the weakening of the immune system with age.
Innovation Solution
Administering agents that decrease the activation of TGF-β receptor or common gamma-chain family cytokine receptors to activate immune cells, such as NK cells, to reduce senescent cell numbers and associated inflammatory factors, thereby targeting senescent cells for elimination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If senolytic drugs are administered to eliminate senescent cells, then the number of senescent cells decreases, but selectivity and safety are compromised due to heterogeneity of senescent cell populations
Solution Approach 1:
The patent uses immune cells (particularly NK cells and macrophages) as intermediary agents to eliminate senescent cells. Instead of directly targeting senescent cells with drugs, the treatment activates the immune system to naturally identify and remove senescent cells through immunosurveillance mechanisms. This intermediary approach resolves the selectivity problem because immune cells can distinguish senescent cells from healthy cells through pattern recognition and activation signals.
Solution Approach 2:
The patent leverages the body's own immune system to perform the elimination of senescent cells. By administering agents that activate immune cells (such as gamma-chain cytokines or TGF-β receptor antagonists), the treatment enables the immune system to self-organize and selectively clear senescent cells without requiring external direct intervention. This self-service mechanism improves safety by avoiding off-target effects on non-senescent cells.
2Quantity of substance
If the immune system is weakened during aging, then senescent cells accumulate, but activating immune cells becomes more difficult
Solution Approach 1:
The patent changes the activation parameters of immune cells by administering specific agents (gamma-chain cytokines like IL-2, IL-7, IL-15, or TGF-β receptor antagonists) that modify the immunological environment. These agents alter the activation threshold and responsiveness of immune cells, enabling them to overcome age-related suppression and effectively target senescent cells even in an aging immune system.
Solution Approach 2:
The treatment applies preliminary activation signals to immune cells before they encounter senescent cells. By pre-activating immune cells through cytokine administration or TGF-β inhibition, the patent ensures that immune cells are in an optimal state to recognize and eliminate senescent cells, compensating for the reduced responsiveness inherent in aged immune systems.
Data Source
AI summary
Provided herein are methods of killing or reducing the number of naturally-occurring and/or treatment-induced senescent cells and diseased cells in a subject in need thereof, decreasing the accumulation of naturally-occurring and/or treatment-induced senescent cells and diseased cells in a subject in need thereof, that include administering to the subject a therapeutically effective amount of one or more common gamma-chain family cytokine receptor activating agent(s) and/or one or more agent(s) that result(s) in a decrease in the activation of a TGF-β receptor.